title: A limitation of the method for siRNA delivery into primary human cytotrophoblast cells.
abstract: Transfection using cationic lipid reagents such as DharmaFECT2 is an efficient tool for introducing siRNA into primary human cytotrophoblast cells. However, we now report a limitation to the use of this method as the concentration of DharamFECT2 needed for effective siRNA delivery causes ligand-independent activation of the insulin/insulin-like growth factor (IGF) receptor and consequently, functional resistance to cytotrophoblast stimulation by these two hormones. We therefore advise researchers against the use of this method of transfection when investigating the mechanisms by which insulin/IGF, and potentially other hormones that exert their effects through kinase signalling molecules, influence cytotrophoblast cell function.
authors.affiliation: Maternal and Fetal Health Research Centre, Developmental Biomedicine, School of Biomedicine, Manchester Academic Health Sciences Centre, University of Manchester, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom. michelle.desforges@manchester.ac.uk
authors.forename: M
authors.initials: M
authors.lastname: Desforges
authors.forename: M
authors.initials: M
authors.lastname: Westwood
mesh_terms: D005260:Female; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D011247:Pregnancy; D034741:RNA, Small Interfering / Q000008:administration & dosage*; D017526:Receptor, IGF Type 1 / Q000187:drug effects; D014162:Transfection / Q000379:methods*; D014327:Trophoblasts / Q000378:metabolism / Q000502:physiology*
chemical_list: D007328:Insulin; D034741:RNA, Small Interfering; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1